Target Name: TENT5D
NCBI ID: G169966
Review Report on TENT5D Target / Biomarker Content of Review Report on TENT5D Target / Biomarker
TENT5D
Other Name(s): CT1.26 | Hypothetical protein LOC169966 | putative nucleotidyltransferase FAM46D | TET5D_HUMAN | CT112 | Terminal nucleotidyltransferase 5D | Cancer/testis antigen 112 | protein FAM46D | terminal nucleotidyltransferase 5D | Non-canonical poly(A) polymerase FAM46D | Terminal nucleotidyltransferase 5D, transcript variant 2 | family with sequence similarity 46 member D | TENT5D variant 2 | OTTHUMP00000023605 | non-canonical poly(A) polymerase FAM46D | MGC26999 | FAM46D | cancer/testis antigen 112

TENT5D: A Potential Drug Target and Biomarker

TENT5D is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell surface marker molecule family and is known for its role in immune regulation. Several studies have identified TENT5D as a potential drug target and biomarker, with potential clinical applications in a variety of diseases.

The identification of TENT5D as a potential drug target comes from its ability to interact with several different signaling pathways. TENT5D has been shown to interact with the PDGF signaling pathway, the NF-kappa-B signaling pathway, and the TGF-β signaling pathway. These interactions make TENT5D a potential target for small molecules that can modulate these signaling pathways and disrupt their activity.

In addition to its potential as a drug target, TENT5D has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that TENT5D may be a useful biomarker for these diseases and could potentially serve as a therapeutic target.

The potential clinical applications of TENT5D as a drug target and biomarker are vast and varied. For example, TENT5D has been shown to be a potential target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. By modulating the activity of TENT5D, researchers may be able to develop new treatments for these debilitating diseases.

In addition to its potential use as a neurodegenerative disease treatment, TENT5D has also been identified as a potential target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By modulating the activity of TENT5D, researchers may be able to develop new treatments for these diseases that are effective and safe.

The identification of TENT5D as a potential drug target and biomarker also has the potential to revolutionize our understanding of the immune system. By modulating the activity of TENT5D, researchers may be able to develop new treatments for a variety of autoimmune diseases and enhance our understanding of the mechanisms that drive these diseases.

In conclusion, TENT5D is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its interactions with multiple signaling pathways make it a promising target for small molecules, and its expression in various tissues make it a promising biomarker for a variety of conditions. Further research is needed to fully understand the potential clinical applications of TENT5D and to develop effective treatments for the diseases that it is associated with.

Protein Name: Terminal Nucleotidyltransferase 5D

Functions: Catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group

The "TENT5D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TENT5D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA